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MetS
. 16 Activation of the renin-angiotensin system (RAS) is the major cause of hypertension because stimulation of the angiotensin II receptor increases oxidative stress, causes endothelial dysfunction, and promotes atherosclerosis. 17 Activation of the RAS has also been associated with abnormal secretion of cytokines in adipose cells. Plasminogen activator inhibitor-1 (PAI-1) is an adipocytokine and an increased level of PAI-1 leads to inadequate fibrinolysis. 18 Endothelial cells also secrete PAI-1 and an increased level of PAI-1 represents endothelial dysfunction. 19 The RAS exerts substantial control over the fibrinolytic system. 20 In fact, infusion of angiotensin II results in a rapid increase in circulating levels of PAI-1 in normotensive subjects and hypertensive patients, which may help to explain clinical observations linking the RAS and thrombotic risk. 21 However, the effect of an angiotensin II receptor blocker (ARB) on the PAI-1 levels in hypertensive patients with MetS has not been elucidated. Therefore, we evaluated the effect of valsartan on adipocytokines in order to identify an optimal antihypertensive treatment for reducing cardiovascular disease in hypertensive patients with MetS.
Methods

Study Design
Kagoshima Collaborate Trial in Metabolic Syndrome (KACTMetS) was an investigator-designed, prospective, multicenter, open-label, randomized, 2 arm parallel-group comparison study (clinicaltrials.gov NCT00790946). Patients recruited from June 2006 to December 2008 from 21 hospitals in Japan were followed for 1 year. The primary objective was to analyze the effect of valsartan on a prothrombotic and proinflammatory state caused by adipocytokine in hypertensive patients with MetS and compare the results with a non-RAS inhibitor group at the same BP levels.
The study design is a response-dependent dose titration schema. The steering committee prepared the randomization method. The study design complied with the Declaration of Helsinki and was unanimously approved by the Ethics Committee of Kagoshima University. Written informed consent was obtained before enrollment from all of the patients who participated in the present study.
Patient Population
KACT-MetS included hypertensive patients with MetS in outpatient clinics. In Japan, MetS is diagnosed when a patient has visceral fat accumulation in addition to having 2 or 3 of the following complicating risk factors: hypertension [defined as systolic BP (SBP) ≥130 mmHg and/or diastolic BP (DBP) ≥85 mmHg or medication], abnormal glucose metabolism (defined as FBG ≥110 mg/dl or medication), and abnormal lipid metabolism [defined as triglycerides (TG) ≥150 mg/dl and/or high-density lipoprotein (HDL) cholesterol <40 mg/dl or medication]. Visceral fat accumulation was defined as waist circumference ≥85 cm in males or ≥90 cm in females. 1 In KACT-MetS, patients with MetS were enrolled when their BP levels were SBP ≥140 and/or DBP ≥90 mmHg. Exclusion criteria were: usage of angiotensin-converting enzyme inhibitor (ACE-I) or ARB within the past 3 months, serum creatinine ≥3 mg/dl, liver impairment, history of allergy to valsartan, pregnancy, menstruation, or judgment by the physician that participation was inappropriate on the basis of the patient's characteristics and drug safety.
Study Procedures
The study design and titration schedule are shown in Figure 1 . Patients registered in this study were randomly assigned to receive either 80-160 mg valsartan per day (valsartan group) or other conventional treatment without ARB or ACE-I (non-RAS inhibitor group). In principle, the target SBP was <140 mmHg and DBP was <90 mmHg in accordance with the JSH2004 guideline. 22 The target BP was set at <130/85 mmHg for patients <65 years old, and <130/80 mmHg for patients with diabetes mellitus or chronic kidney disease. Whether the patient achieved the target BP was checked at 1 and 3 months. The dose of current medication was titrated or use of other medications was permitted to achieve the target BP.
In the valsartan group, treatment was started at 80 mg and increased to 160 mg to achieve the target BP in patients previously untreated for hypertension. For patients who had received antihypertensive therapy prior to enrollment, valsartan 80 mg was added to the current medication, or the patient was Figure 1 . Scheme of study design. ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; RAS, renin-angiotensin system. Valsartan Reduces PAI-1 in MetS switched to valsartan 160 mg. Regardless of previous treatment, patients who failed to achieve the target BP with valsartan 160 mg were to concurrently receive low-dose diuretic and/or calcium-channel blocker. Combined use of β-blocker and/or α-blocker was also allowed, depending on the condition of the disease.
In the non-RAS inhibitor group, treatment was started with calcium-channel blocker, diuretic, β-blocker or α-blocker at the usual recommended dose in previously untreated patients. The dose was increased or other antihypertensive drugs concurrently used in patients who failed to achieve the target BP. The dose of current medication was increased in patients who had been treated for hypertension. Regardless of previous treatment, patients who failed to achieve the target BP received an additional antihypertensive drug other than a RAS inhibitor.
Use of medications for the treatment of complications was allowed; however, in principle, dose increase and additional medications were disallowed after starting the study treatment. Concomitant therapies for the treatment of hypertension or complications (eg, diet and exercise) were continued.
Evaluation of Outcomes
The primary endpoint was changes in adiponectin and PAI-1 antigen levels between the valsartan and non-RAS inhibitor groups when BP was equally controlled. The secondary endpoints were changes in the levels of tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), FBG, homeostasis model assessment of insulin resistance (HOMA-IR), HbA1c, TG, HDLcholesterol, B-type natriuretic peptide (BNP) and asymmetric dimethylarginine (ADMA) in the 2 groups. [HbA1c (%)=HbA1c Japan Diabetes Society (JDS) (%)+0.4%, considering the relational expression of HbA1c (JDS) (%) measured by the previous Japanese standard substance and measurement methods and HbA1c (NGSP) 23 ]. A fasting blood sample was taken in the morning and all blood testing was performed at a single institution. BP was measured at the office on 2 different occasions with a calibrated mercury sphygmomanometer after a 5-min rest while seated.
Standard 2-dimensional echocardiographic examinations were performed using 1-to 5-MHz phased array transducers and commercially available scanners. 24 Posterior wall thickness (PWT), interventricular septal thickness (IVS), left ventricular systolic (LVDs) and diastolic (LVDd) dimensions were determined. Left ventricular (LV) mass was calculated by the ASE-recommended formula: 25
LV mass was divided by body surface area to obtain the LV mass index (LVMI).
Animal Study
In order to clarify the effect of RAS inhibition on the expression of PAI-1, we performed the following animal experiment. We used male apolipoprotein E (apoE) knockout (apoE −/− ) mice and angiotensin II type 1a receptor (AT1a) knockout (AT1a −/− ) mice. The double knockout (D-KO) mice of AT1a and apoE were made by cross-breeding apoE −/− and AT1a −/− mice as described previously. 26 All animals were allowed food and water ad libitum. 
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This animal study was carried out in accordance with the Guide for Animal Experimentation of the Faculty of Medicine at Kagoshima University. The animals were humanely killed with an overdose of sodium pentobarbital at the age of 45 weeks, and the aortas and adipose tissues were harvested, snap-frozen in liquid nitrogen and stored at −80°C for use in western blot analyses.
Western Blot Analysis
We examined the difference between apoE −/− and D-KO mice in PAI-1 expression in the aorta and adipose tissue. We extracted sample proteins and performed the analysis as reported previously. 27 Briefly, western blotting was performed with a NuPAGE Electrophoresis System (Novex, San Diego, CA, USA). Twenty-μg protein samples were resuspended in a reduced sample buffer, and then electrophoresed on a 4-12% Bis-Tris gel (Novex, San Diego, CA, USA) with MOPS running buffer, blotted to nitrocellulose, and sequentially probed with polyclonal rabbit antisera raised for PAI-1 or actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). A horseradish peroxidase-conjugated goat anti-rabbit antibody (Santa Cruz Biotechnology) was then added, and secondary antibodies were detected through autoradiography using enhanced chemiluminescence (GE Healthcare UK Ltd, Little Chalfont, UK). The expression of PAI-1 was quantified by the expression of actin. Data are mean ± SD or n (%). BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PAI-1, plasminogen activator inhibitor-1; HDL, high-density lipoprotein; HbA1c, hemoglobin A1c; FBG, fasting blood glucose; HOMA-IR, homeostasis model assessment of insulin resistance; ADMA, asymmetric dimethylarginine; BNP, B-type natriuretic peptide; LVMI, left ventricular mass index; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α. Valsartan Reduces PAI-1 in MetS
Statistical Analysis
Values are expressed as mean ± SD, except for changes in the mean value after 1 year, which are expressed as mean ± SE. Analysis was made by an independent statistical analysis organization based on the intention-to-treat principle. The difference between treatment groups was tested using a paired t-test. Treatment efficacy was evaluated based on the intergroup mean difference in change and 95% confidence interval (CI). Statistical significance was evaluated using unpaired Student's t-tests for comparisons between 2 groups in the animal experiments. The correlation between the changes in PAI-1 levels and other values was analyzed by linear regression analysis. The JMP version 8.01 was used for the analysis. A probability value <0.05 was considered to be statistically significant.
Results
Clinical Study
205 hypertensive patients with MetS were randomly assigned to either the valsartan or non-RAS inhibitor group and finally there were 79 and 71 patients, respectively, for analysis (Figure 2 ). There were no significant differences between the valsartan and non-RAS inhibitor groups in the patients' characteristics, antihypertensive medications, treatment for complications or concomitant therapies at baseline except for heart rate ( Table 1) . The risk factors identified in MetS patients participating in this study were comparable between the valsartan and non-RAS inhibitor groups: hypertension+abnormal glucose metabolism in 19 patients (24%) and 15 patients (21%); hypertension+abnormal lipid metabolism in 31 patients (39%) and 28 patients (41%); hypertension+abnormal glucose metabolism+abnormal lipid metabolism in 29 patients (37%) and 28 patients (38%), respectively. After 1 year, there were no significant differences between the 2 groups for changes in SBP and DBP (SBP in valsartan group: 153±15 to 138±16 mmHg; non-RAS inhibitor group: 150±14 to 137±15 mmHg, P=0.45; DBP in valsartan group: 86±15 to 77±12 mmHg; non-RAS inhibitor group: 82±15 to 76±10 mmHg, P=0.26) (Figure 3) . In addition, there were no significant differences between the 2 groups in the BP levels at 1 year. There were no significant intergroup differences in waist circumference, weight and body mass index (BMI). Although the absolute value of PAI-1 level tended to decrease in the valsartan group and increase in the non-RAS inhibitor group after 1 year, the absolute PAI-1 levels did not reach a significant difference in either group (valsartan: 39±25 to 35±21 ng/ml, n=59, P=0.38; non-RAS inhibitor group: 32±25 to 38±41 ng/ml, n=56, P=0.36). However, there was a significant difference between the valsartan and non-RAS inhibitor groups in the change in PAI-1 level after 1 year (valsartan group: −3.7±3.2 ng/ml; non-RAS inhibitor group: 5.8±3.3 ng/ml; mean difference between groups −9.5±4.6 ng/ml, 95%CI -0.4 to −18.6, P=0.04; Figure 4A ). There were no significant differences between the 2 groups after 1 year in the changes in the concentrations of adiponectin (valsartan group: 0.3±0.4 μg/ml; non-RAS inhibitor group: 0.9±0.4 μg/ml; mean difference between groups, 0.6±0.5 μg/ml; 95%CI −0.39 to 1.7; P=0.22, Figure 4B ), TNF-α, IL-6, FBG, HOMA-IR, HbA1c, TG, HDLcholesterol, and ADMA, or in LVMI ( Table 2) . Furthermore, we analyzed the correlation between the changes in PAI-1 level and the factors of MetS ( Table 3) . Although a change in PAI-1 level significantly correlated with changes in BMI, TG and HbA1c in the non-RAS inhibitor group, there was not a significant correlation with the changes in these factors, except for ADMA level, in the valsartan group. 
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Both treatments were well-tolerated and associated with few adverse events, although 2 serious adverse events were reported. Nonfatal myocardial infarction occurred in 1 patient in the valsartan group, but the study treatment was continued. This patient was at a high risk for cardiovascular disease, with the highest baseline BNP (672 pg/ml). 1 patient in the non-RAS inhibitor group dropped out because of polymyalgia rheumatica syndrome.
Animal Experiments
We used western blot analysis to quantify and compare the expression of PAI-1 in the aorta and adipose tissue of apoE −/− and D-KO mice at 45 weeks of age ( Figure 5) . The aortic expression of PAI-1 in D-KO mice was significantly lower than that in apoE −/− mice (apoE −/− vs. D-KO=1.26±0.17 vs. 0.74± 0.26, n=4 per group, P=0.02), whereas there was no significant difference in the PAI-1 expression of adipose tissue between apoE −/− and D-KO mice (apoE −/− vs. D-KO=0.63±0.15 vs. 0.77±0.05, n=4 per group, P=0.15). 
Discussion
We conducted the KACT-MetS study to verify our hypothesis that antihypertensive therapy with a RAS inhibitor is superior to traditional antihypertensive therapy because of the inhibition of abnormal secretion in adipose cells and activation of the fibrinolytic system in hypertensive patients with MetS whose BP is equally controlled. Although there was no significant difference between the treatment groups in adiponectin levels, PAI-1 was significantly decreased in the valsartan group compared with the non-RAS inhibitor group. This study enrolled MetS patients with diabetes and/or hyperlipidemia in addition to visceral fat accumulation and hypertension. There was no significant difference between the treatment groups in waist circumference, weight, BMI, TG, HDL-cholesterol or HbA1c at 1 year. Only PAI-1 was significantly decreased in the valsartan group compared to the non-RAS inhibitor group. On the other hand, baseline adiponectin was within the normal range and not associated with waist circumference. There was no difference in the overall change in adiponectin levels at 1 year. In other words, the enrolled patients may not have had abnormal secretion of adiponectin in adipose cells, or adipose cell dysfunction.
We previously reported that arteriosclerosis formation was suppressed in D-KO mice created by mating apoE −/− mice (a hyperlipidemia-induced arteriosclerosis model) with AT1a −/− mice compared with apoE −/− mice. 26 In addition, the present study showed that aortic PAI-1 protein expression was reduced in D-KO mice compared with apoE −/− mice, suggesting that inhibition of the RAS is involved in the reduction of PAI-1 expression in the arteries. We have reported that markers of oxidative stress and inflammation were reduced in D-KO mice compared to apoE −/− mice. 26 Taken together, these results show that combined reduction in oxidative stress, inflammation and fibrinolysis may help prevent the development of atherosclerosis.
PAI-1 is synthesized and released by many cell types, including adipocytes, endothelial cells and platelets. Although we could not identify the main cell source of the PAI-1 reduction by valsartan in the present clinical study, the animal study demonstrated that PAI-1 expression was decreased in the aorta of D-KO mice compared to apoE −/− mice, but did not change in the adipose tissue. Therefore, we speculate that ARB may decrease PAI-1 release mainly from arteries.
The risk factors for MetS consistently involve insulin resistance, which is thought to be associated with activation of the coagulation/fibrinolytic system. Past epidemiological studies showed that PAI-1 is related to insulin resistance, and elevated PAI-1 was associated with an increased incidence of cardiovascular events. 28 Although the change in PAI-1 level significantly correlated with changes in BMI, TG, and HbA1c in the non-RAS inhibitor group of the present study, it did not show a significant correlation with changes in these factors, except for ADMA level, in the valsartan group. These results suggest that the reduction in PAI-1 level by valsartan may be independent of the factors of MetS.
Valsartan effectively inhibits angiotensin II-induced PAI-1 secretion without affecting the secretion of tissue plasminogen activator (tPA) in rat and human arterial smooth muscle cells. 29 A study in postmenopausal women showed that valsartan tended to decrease PAI-1 compared to other ARBs. 30 A number of Japanese studies of valsartan have been published. 31- 35 The Jikei Heart Study showed that adding valsartan to conventional therapies reduced the risk of events in hypertensive patients with cardiovascular disease. 33 A similar reduction in cardiovascular events was reported in the Kyoto Heart Study of patients with uncontrolled hypertension. 34 In the Nagoya Heart Study, valsartan reduced the heart failure incidence in patients with hypertension complicated with diabetes or impaired glucose tolerance. 35 A hypothetical mechanism of the cardiovascular event inhibition suggested in those studies was described in our KACT-MetS, which indicated that valsartan improves the fibrinolytic state by reducing the circulating PAI-1 level better than traditional antihypertensive treatment.
Study Limitations
The KACT-MetS did not use a hard endpoint for the evaluation. The association of PAI-1 reduction by valsartan with cardiovascular events needs to be further evaluated in a larger sample. Because the adiponectin level was within normal limits in the hypertensive patients with MetS enrolled in this study, it is still unknown whether valsartan increases the adiponectin level. The effect of valsartan on adiponectin levels needs to be studied in MetS patients with decreased adiponectin. We should have measured the level of tPA antigen or activity to confirm the fibrinolytic activity, because fibrinolytic activity is determined by the balance between the levels of PAI-1 and tPA.
Conclusions
Valsartan reduced plasma PAI-1 levels compared to non-RAS inhibitor treatment in hypertensive patients with MetS, which suggests it may be useful for improving fibrinolytic function.
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